Profile
Stéphane R.
Méry currently works at Contronics Ltd., as Chief Executive Officer.
Dr. Méry also formerly worked at Smithkline Beecham Plc, as Associate Director-Worldwide Business Development, GSK Plc, as Associate Director-Worldwide Business Development, ImmuPharma Plc, as Independent Non-Executive Director from 2015 to 2021, Population Genetics Technologies Ltd., as Director, Domainex Ltd., as Non-Executive Director, PolyTherics Ltd., as Director, Altacor Ltd., as Non-Executive Director, Genex Biosystems Ltd., as Director, GlaxoSmithKline LLC, as Associate Director, Amati Global Investors Ltd. (Venture Capital), as Director, Worldwide Business Development Corp., as Associate Director, Endomagnetics Ltd., as Director, Beringea LLP, as Partner from 2008 to 2014, and Bloomsbury Bioseed Fund Ltd, as Fund Manager from 2000 to 2020.
Dr. Méry received his Masters Business Admin degree from INSEAD.
Stéphane Méry active positions
| Companies | Position | Start |
|---|---|---|
Contronics Ltd.
Contronics Ltd. Industrial MachineryProducer Manufacturing Manufactures and installs temperature monitoring systems | Chief Executive Officer | - |
Former positions of Stéphane Méry
| Companies | Position | End |
|---|---|---|
| IMMUPHARMA PLC | Director/Board Member | 30/07/2021 |
Bloomsbury Bioseed Fund Ltd
Bloomsbury Bioseed Fund Ltd Investment ManagersFinance Bloomsbury Bioseed Fund invests in companies located in the United Kingdom. The firm focuses on a broad range of sectors. It participates in early-stage transactions. | Private Equity Investor | 14/02/2020 |
Beringea LLP
Beringea LLP Investment ManagersFinance Beringea is an active manager which invests in dynamic businesses led by exceptional management in the healthcare, media, brands and intellectual property sectors, partnering with investee businesses to provide resources to develop strategy, evaluate growth opportunities, solve problems and build value. Their ProVen VCT invests in a diversified portfolio of unquoted and AIM-listed companies with the potential for significant value increases. After investing, the firm remains closely involved in the investee businesses, aiming to add value wherever possible and seeking to identify opportunities for profitable exits as the company's value increases. The firm's PGI VCT specializes in early-stage and growth company investments across a range of sectors. Beringea's InvestCare Partners, LP provides equity to medium-sized, privately owned mid- to late-stage US healthcare businesses, typically investing between $2 and $5 million. Their Global Rights Fund II invests in all growth stages of US and UK media, content, brands, enabling technology and intellectual property rights companies, seeking to exploit intellectual property rights across media platforms. Beringea typically invests $1-$5 million in Global Rights Fund II companies. | Private Equity Investor | 01/12/2014 |
Genex Biosystems Ltd.
Genex Biosystems Ltd. BiotechnologyHealth Technology Develops pharmaceutical products for vascular diseases | Director/Board Member | 16/02/2012 |
Amati Global Investors Ltd. (Venture Capital)
Amati Global Investors Ltd. (Venture Capital) Investment ManagersFinance AGI-VC investing in small and mid-sized companies in the United Kingdom. It invests in both public& private companies. It provides equity and convertible loans financing for growth/later stage capital requirements. | Private Equity Investor | 01/02/2009 |
Training of Stéphane Méry
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Beringea LLP
Beringea LLP Investment ManagersFinance Beringea is an active manager which invests in dynamic businesses led by exceptional management in the healthcare, media, brands and intellectual property sectors, partnering with investee businesses to provide resources to develop strategy, evaluate growth opportunities, solve problems and build value. Their ProVen VCT invests in a diversified portfolio of unquoted and AIM-listed companies with the potential for significant value increases. After investing, the firm remains closely involved in the investee businesses, aiming to add value wherever possible and seeking to identify opportunities for profitable exits as the company's value increases. The firm's PGI VCT specializes in early-stage and growth company investments across a range of sectors. Beringea's InvestCare Partners, LP provides equity to medium-sized, privately owned mid- to late-stage US healthcare businesses, typically investing between $2 and $5 million. Their Global Rights Fund II invests in all growth stages of US and UK media, content, brands, enabling technology and intellectual property rights companies, seeking to exploit intellectual property rights across media platforms. Beringea typically invests $1-$5 million in Global Rights Fund II companies. | Finance |
INSEAD
INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmuPharma Plc
ImmuPharma Plc Pharmaceuticals: OtherHealth Technology Discovers and develops pharmaceutical drugs | Health Technology |
Population Genetics Technologies Ltd.
Population Genetics Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Offers population genetics studies | Commercial Services |
Domainex Ltd.
Domainex Ltd. BiotechnologyHealth Technology Operates as a drug discovery company | Health Technology |
PolyTherics Ltd.
PolyTherics Ltd. Pharmaceuticals: MajorHealth Technology Develops biomedical polymers for therapeutic applications | Health Technology |
Altacor Ltd.
Altacor Ltd. Pharmaceuticals: MajorHealth Technology Operates as a ophthalmology company which develops and markets a portfolio of products in fields of dry eye, glaucoma & ocular infection | Health Technology |
Genex Biosystems Ltd.
Genex Biosystems Ltd. BiotechnologyHealth Technology Develops pharmaceutical products for vascular diseases | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Amati Global Investors Ltd. (Venture Capital)
Amati Global Investors Ltd. (Venture Capital) Investment ManagersFinance AGI-VC investing in small and mid-sized companies in the United Kingdom. It invests in both public& private companies. It provides equity and convertible loans financing for growth/later stage capital requirements. | Finance |
Bloomsbury Bioseed Fund Ltd
Bloomsbury Bioseed Fund Ltd Investment ManagersFinance Bloomsbury Bioseed Fund invests in companies located in the United Kingdom. The firm focuses on a broad range of sectors. It participates in early-stage transactions. | Finance |
Worldwide Business Development Corp.
Worldwide Business Development Corp. Financial ConglomeratesFinance Provides investment services | Finance |
Endomagnetics Ltd.
Endomagnetics Ltd. Packaged SoftwareTechnology Services Develops breast cancer surgery technology | Technology Services |
Contronics Ltd.
Contronics Ltd. Industrial MachineryProducer Manufacturing Manufactures and installs temperature monitoring systems | Producer Manufacturing |
- Stock Market
- Insiders
- Stéphane Méry
















